Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study-Reference-Cited by-同舟云学术

Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study

Published:2022-07 Issue: Volume:Volume 12 Page:199-204
ISSN:2230-326X
Container-title:Psoriasis: Targets and Therapy
language:en
Short-container-title:PTT

Author:

Megna Matteo,Fornaro Luigi,Potestio Luca^ORCID,Luciano Maria Antonietta,Nocerino Mariateresa,Delfino Mario,Guarino Maria,Fabbrocini Gabriella,Camela Elisa^ORCID

Publisher

Informa UK Limited

Subject

Dermatology,Rheumatology

Reference17 articles.

1. An Overview of Biologics for Psoriasis

2. Padda IS, Bhatt R, Rehman O, Parmar M. Biosimilars Use in Medicine for Inflammatory Diseases. Treasure Island (FL); 2022.

3. World Health Organization. Guidelines on Evaluation of Biosimilars. Geneva: WHO; 2022: 1–52.

4. Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and Safety of Biosimilars in Pediatric Non-infectious Uveitis: Real-Life Data from the International AIDA Network Uveitis Registry;Ophthalmology and Therapy;2024-01-11

2. Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review;Dermatology and Therapy;2023-09-14

3. [Translated article] Updated Position of the Spanish Psoriasis Group (GPs) on the Use of Biosimilar Drugs in Moderate to Severe Psoriasis;Actas Dermo-Sifiliográficas;2023-06

4. Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?;Clinical, Cosmetic and Investigational Dermatology;2023-06

5. d-mannose blocks the interaction between keratinocytes and Th17 cells to alleviate psoriasis by inhibiting HIF-1α/CCL20 in mice;International Immunopharmacology;2023-05